Abstract
Intestinal acyl-CoA:diacylglycerol acyltransferase 2 (DGAT2) is important in the cellular and physiological responses to dietary fat. To determine the effect of increased intestinal DGAT2 on cellular and physiological responses to acute and chronic dietary fat challenges, we generated mice with intestine-specific overexpression of DGAT2 and compared them with intestine-specific overexpression of DGAT1 and wild-type (WT) mice. We found that when intestinal DGAT2 is present in excess, triacylglycerol (TG) secretion from enterocytes is enhanced compared to WT mice; however, TG storage within enterocytes is similar compared to WT mice. We found that when intestinal DGAT2 is present in excess, mRNA levels of genes involved in fatty acid oxidation were reduced. This result suggests that reduced fatty acid oxidation may contribute to increased TG secretion by overexpression of DGAT2 in intestine. Furthermore, this enhanced supply of TG for secretion in Dgat2Int mice may be a significant contributing factor to the elevated fasting plasma TG and exacerbated hepatic TG storage in response to a chronic HFD. These results highlight that altering fatty acid and TG metabolism within enterocytes has the capacity to alter systemic delivery of dietary fat and may serve as an effective target for preventing and treating metabolic diseases such as hepatic steatosis.
Keywords: Acyl-CoA:diacylglycerol acyltransferase, Chylomicron, Cytoplasmic lipid droplet, Dietary fat absorption, Triacylglycerol, Intestine
1. Introduction
When present in excess, dietary fat contributes to health problems including obesity, diabetes, heart disease, and hepatic steatosis. Dietary fat in excess can instigate health problems due to its high energy density and its impact on blood lipid concentrations. Dietary fat absorption is a highly efficient process with greater than 95% of dietary fat absorbed whether the diet is high or low in dietary fat [1]. Dietary fat, in the form of triacylglycerol (TG), is hydrolyzed in the intestinal lumen to monoacylglycerol and free fatty acids. These digestive products are then taken up by the absorptive cells of the intestine, enterocytes, and are primarily incorporated into TG either for secretion on TG-rich lipoproteins, chylomicrons (CM), or storage in cytoplasmic lipid droplets (CLDs) [2,3]. The storage and secretion of TG by enterocytes are dynamic and dose dependent processes. TG storage in CLDs within enterocytes and TG secretion from enterocytes initially increase and then decrease over time after a meal containing fat [2,4,5]. Recently, we and others have demonstrated that it is not only the amount of fat, but also the rate that dietary fat is delivered in blood to other tissues that contributes to some health problems associated with dietary fat [4,6]. Therefore, discerning the factors that regulate the balance between TG storage and secretion within enterocytes is critical to our mechanistic understanding of the contribution of dietary fat to these health problems.
The final and committed step in TG biosynthesis is the acylation of diacylglycerol with a fatty acid by acyl-CoA:diacylglycerol acyltransferase (DGAT). In mammals, there are two known, non-homologous proteins catalyzing DGAT activity: DGAT1 and DGAT2. DGAT1 and DGAT2 are both expressed ubiquitously; however, their relative tissue and cellular expression patterns are distinct [7,8]. Specifically, DGAT1 is most abundant in the small intestine, whereas DGAT2 is most abundant in adipose tissue and liver. In mouse intestine, the expression pattern of DGAT1 and DGAT2 is similar; highest in the proximal intestine and lowest in the distal intestine [8]. In human intestine, DGAT1 is abundant; however, DGAT2 may be present in much lower levels or even absent [9,10]; however, a thorough evaluation of DGAT2 expression in human enterocytes has not been done. Intracellularly, DGAT1 and DGAT2 both localize to the endoplasmic reticulum; however, DGAT2 has also been identified on CLDs [11,12] and in mitochondria associated membranes [12]. The ability to synthesize TG directly on CLDs contributes to the expansion of CLD size [11]. In addition to their different biochemical properties, these differences in expression patterns contribute to their different cellular and physiological functions [13,14].
In enterocytes, DGAT1 plays an important role in determining the balance between TG storage and secretion, and determining the systemic fate of dietary fat. Although Dgat1−/− mice quantitatively absorb dietary fat similarly to wild-type (WT) mice and can make CMs, their process of dietary fat absorption is altered. Dgat1−/− mice accumulate abnormally high levels of TG in CLDs within enterocytes when fed a high fat diet (HFD) and secrete TG slowly compared to WT mice [8]. Similar results have also been reported in WT mice treated with DGAT1 inhibitors [15–18]. In addition, mice with intestine-specific overexpression of DGAT1 (Dgat1Int) store abnormally low levels of TG within enterocytes when fed a HFD, but secrete TG at a similar rate compared with WT mice [4]. Finally, despite lacking DGAT1 in adipose tissue and liver, mice with DGAT1 expression only in the intestine (Dgat1Int crossed with Dgat1−/− mice), are susceptible to HFD induced obesity and hepatic steatosis. Collectively, these results suggest that intestinal DGAT1 is not required for CM synthesis and secretion, but is important in the trafficking of dietary fat within enterocytes and systemically. These results also suggest that DGAT2 makes TG for storage and secretion in the absence of DGAT1, but the balance is altered. Clearly, DGAT1 and DGAT2 are working together in enterocytes to synthesize TG and mediate efficient dietary fat absorption.
The role of DGAT2 in intestine is less clear due to the fact that Dgat2−/− mice die shortly after birth [19]. DGAT2, but not DGAT1, mRNA levels in mouse intestinal mucosa increase in response to both acute and chronic HF dietary challenges [5]. In addition, DGAT2 mRNA levels in small intestine of obese and diabetic mouse strains (ob/ob, db/db and KK-Ay) are higher than in control mice [5,20,21]. To determine the effect of increased intestinal DGAT2 in the small intestine on cellular and physiological responses to acute dietary fat challenges and chronic HFD feeding, we generated mice with intestine-specific overexpression of DGAT2 (Dgat2Int) and compared them with WT and Dgat1Int mice. Although the basic phenotype of Dgat1Int mice has previously been reported [4], we included Dgat1Int mice in these experiments so we could compare high DGAT2/DGAT1 (Dgat2Int), normal DGAT2/DGAT1 (WT), and low DGAT2/DGAT1 (Dgat1Int) ratios in enterocytes on TG metabolism.
2. Materials and methods
2.1. Diets and mice
All procedures were approved by the Purdue Animal Care and Use Committee. The VILL-Dgat2 transgene was made with a 12.4-kb VILL promoter/enhancer from the pUC12.4-kb-villin plasmid (Dr. Deborah L. Gumucio, University of Michigan, Ann Arbor, Michigan) and a 1.2-kb Dgat2 cDNA sequence from the MDGAT2αF(MDC1F)/pcDNA3 plasmid (Dr. Robert V. Farese Jr, Gladstone Institutes, San Francisco, California). The final transgene clone containing the villin promoter/enhancer and mouse Dgat2 cDNA was verified by restriction mapping and sequence analysis. The transgene was prepared by digestion with PmeI and purification before introduction into C57BL/6 fertilized eggs by microinjection (Purdue Transgenic Core Facility, Purdue University, West Lafayette, Indiana). Founder animals were backcrossed with C57BL/6 mice to generate mice with intestine-specific overexpression of Dgat2. Two lines of mice with either 4- or 9-fold overexpression of Dgat2 mRNA compared to WT were generated. Results presented are for the line with 4-fold overexpression of Dgat2 mRNA levels compared to WT mice, and are referred to as Dgat2Int. Similar results for the line with 9-fold overexpression of Dgat2 mRNA levels compared to WT mice were found and are reported as Dgat2IntB in the Supplementary data. Male Dgat1Int mice (intestine-specific 20-fold overexpression of Dgat1 mRNA level compared to WT mice) were generated as previously described [4]. Dgat1Int and Dgat2Int were crossed with Dgat1−/− mice to generate Dgat1−/−Dgat1Int and Dgat1−/−Dgat2Int mice.
All mice enrolled in the studies described were male and maintained in a specific pathogen-free barrier facility with a 12-hour light/dark cycle (6AM/6PM). Mice were fed, either a low-fat, rodent chow diet (PicoLab 5053, Lab Diets, Richmond, IN), or a HFD (D12492, Research Diets, Inc., New Brunswick, NJ) for the indicated times. For chow diet (3.4 kcal/g), 62.1% of calories came from carbohydrate (starch), 24.7% from protein, and 13.2% from fat. For HFD (5.24 kcal/g), 20% of calories came from carbohydrate (35% sucrose, 65% starch), 20% from protein, and 60% from fat (mostly lard). Mice were enrolled in body weight studies at 10 weeks of age and fed indicated diets for 9 weeks. Mice not enrolled in body weight studies were 3–5 months of age and fed indicated diets.
Mice were euthanized and tissues harvested at specific time points relative to the fed-fasted cycle. Fed: For mice representing the fed state, food was removed at the beginning of the light cycle (6AM) and mice were euthanized at 8AM. The 2 h of food removal was at a time period where mice are normally not eating and was intended to minimize the variability in time since last food consumption. Time course: For the time course, all mice had food removed for 4 h prior to a 200 μl olive oil gavage and were euthanized at baseline, and 1, 2, 4, or 8 h post-gavage. After administration of the olive oil gavage, no other food was available during the time course. For analysis, we divided the small intestine into six equal-length segments and labeled them S1–S6 (proximal to distal). We scraped mucosa from each region of the intestine for RT-PCR, QPCR, and intestinal TG quantification.
2.2. Genotyping
Genotyping for Dgat2Int was performed on genomic DNA extracted from tails to determine the presence or absence of transgene and/or endogenous gene. Primer sets Forward 5′-GAGTGGCCTGCAGTGTCATCC-3′ and Reverse 5′-GGATGGGAAAGTAGTCTCGGAAGTAGC-3′ were used to detect the presence of a transgene, amplifying a 177 bp product in transgenic mice and 505 bp product in WT mice. Genotyping for Dgat1Int and Dgat1−/− mice was performed as previously described [4].
2.3. Fasting plasma TG and glucose concentration
Mice were fasted for 12 h, and blood samples were obtained from the submandibular vein. TG concentration was determined by Wako L-Type TG determination kit (Wako Chemicals USA) and glucose concentration was determined by OneTouch glucometer (LifeScan, Milpitas, CA).
2.4. Postprandial triglyceridemic response
Mice were fasted for 4 h starting at the beginning of the light cycle, and administered an oral gavage of 200 μl olive oil and blood collected via submandibular vein up to 4 h post-gavage. Plasma TG concentration was determined by Wako L-Type TG determination kit (Wako Chemicals USA, Richmond, VA).
2.5. Hepatic and intestinal TG secretion
Mice were fasted for 4 h starting at the beginning of the light cycle and administered 500 mg/kg Tyloxapol (T0307, Sigma-Aldrich, St. Louis, MO) via IP injection to block lipase activity in circulation. For hepatic TG secretion, blood was collected from the submandibular vein 1, 2 and 4 h post Tyloxapol injection. For intestinal TG secretion, 30 min post-Tyloxapol injection, mice were given 200 μl olive oil via oral gavage and blood collected via the submandibular vein 2 and 4 h post-gavage. Plasma TG concentration was determined by Wako L-Type TG determination kit (Wako Chemicals USA).
2.6. CM size
CMs were isolated from plasma collected 1 h post 200 μl olive oil oral gavage. Briefly, PBS was layered on to 50 μl plasma in a 230 μl polycarbonate thickwall ultracentrifuge tube and spun for 30 min at 50,000 ×g in a bench top ultracentrifuge (Optima Max XP, Beckman Coulter, Brea, CA) and the top layer collected. Dynamic light scattering (DLS) was used to measure hydrodynamic diameter of CMs. DLS measurements (three repeated measurements per sample) were taken at room temperature using the automatic mode on the Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) to choose the appropriate settings for run length and number of runs per measurement. The Z averages, dominant intensity peak, and polydispersity indices are reported. The Z average is the intensity weighted mean hydrodynamic size of the entire population of CMs. The dominant intensity peak indicates only the most prominent chylomicron population. The polydispersity index is related to the standard deviation of the hypothetical Gaussian distribution of particle size. Both are derived from cumulant analysis of the DLS measured intensity autocorrelation function [5,22,23].
2.7. Dietary fat absorption
In singly housed cages, food intake was determined over 5 days and feces were collected daily. The feces were dried for 2 h in an ANKOMRD dryer (ANKOM Technology, Macedon, NY) and then lipids were extracted by automated Soxhlet extraction (petroleum ether) using the ANKOMXT15 extraction system (ANKOM Technology). The analysis is achieved by measuring the loss of mass due to the extraction of fat from the dried fecal samples.
2.8. Intestinal and liver TG concentrations
Lipids in intestinal mucosa (S2 and S3, representing jejunum) and liver were extracted by the hexane/isopropanol method. Briefly, after homogenization of the mucosa with 1 M Tris–HCL (pH 7.4), hexane/isopropanol (3:2) and water were added to the sample and it was incubated for 30 min with occasional mixing. The upper organic layer was evaporated under nitrogen and lipids were dissolved in isopropanol. TG concentration was determined by Wako L-Type TG determination kit (Wako Chemicals USA) and normalized to protein concentration (Pierce, Rockford, IL).
2.9. Tissue imaging
For intact tissue imaging, ex vivo fresh tissues from small intestine (S2, representing upper jejunum, and S4, representing lower jejunum) were placed in 3 ml Dulbecco's Modified Eagle's Medium (Gibco, Carlsbad, CA) supplemented with 20 mM HEPES, 100 U/ml penicillin–streptomycin (Gibco), and 10% fetal bovine serum. Tissues kept at 4 °C maintained good morphology over 5 h. Small intestine tissue was cut longitudinally and laid flat for luminal imaging. All tissues were imaged within 3 h after euthanasia. Coherent anti-Stokes Raman scattering (CARS) imaging was performed using a multimodal microscope as previously described [5].
2.10. RT-PCR and QPCR
Total RNA was extracted from tissues with RNA STAT60 (Tel-Test, Friendswood, TX) and then DNase treated with Turbo DNA-free (Ambion, Austin, TX). cDNA was synthesized from 1 μg DNase treated RNA by AffinityScript qPCR cDNA using oligo dT and random hexamer primers (Stratagene, La Jolla, CA). QPCR and RT-PCR were performed using Mx3000P QPCR System (Stratagene) and Brilliant SYBR green master mix (Stratagene) or GoTaq Green master mix (Promega, Madison, WI), respectively. The expression of each gene was normalized to 18S rRNA and calculated with the comparative Ct method. For determination of tissue-specific transgene expression in Dgat2Int mice, a primer sequence partially upstream of the Dgat2 transgene, Forward 5′-CTTCTCCTCTAGGCTCGTCCACCC-3′, and the reverse primer within the transgene, Reverse 5′-TCTTGGGCGTGTTCCAGTCAAATG-3′, were used for RT-PCR. QPCR primers used for this study were all validated for efficiency and correct product size in cDNA from mouse intestinal mucosa (Table 1).
Table 1.
Gene | Primer sequences |
---|---|
18S rRNA | F 5′-TTAGAGTGTTCAAA GCAGGCCCGA-3′ |
R 5′-TCTTGGCAAATGCTTTCGCTCTGG-3′ | |
Acadl | F 5′-TTGCTTGGCATCAACATCGCGAG-3′ |
R 5′-TGTCATGGCTATGGCACCGATACA-3′ | |
Acadm | F 5′-TCGGTGAAGGAGCAGGTTTCAAGA-3′ |
R 5′-AAACTCCTTGGTGCTCCACTAGCA-3′ | |
Acox | F 5′-ATATTTACGTCACGTTTACCCCGG-3′ |
R 5′-GGCAGGTCATTCAAGTACGACAC-3′ | |
Cpt1a | F 5′-TGTGGTGTCCAAGTATCTGGCAGT-3′ |
R 5′-AACACCATAGCCGTCATCAGCAAC-3′ | |
Dgat1 | F 5′-ACCGCGAGTTCTACAGAGATTGGT-3′ |
R 5′-ACAGCTGCATTGCCATAGTTCCCT-3′ | |
Dgat2 | F 5′-TGGGTCCAGAAGAAGTTCCAGAAGTA-3′ |
R 5′-ACCTCAGTCTCTGGAAGGCCAAAT-3′ | |
Fabp2 | F 5′-AGAGGAAGCTTGGAGCTCATGACA-3′ |
R 5′-TCGCTTGGCCTCAACTCCTTCATA-3′ | |
Pparα | F 5′-TCGCGTACGGCAATGGCTTTATCA-3′ |
R 5′-AGCTTTGGGAAGAGGAAGGTGTCA-3′ |
2.11. Data and statistics
All the data are shown as mean ± SEM. Statistical differences were evaluated with one-way ANOVA followed by a Tukey HSD test between groups, or a T-test where appropriate (P < 0.05).
3. Results
3.1. Generation of mice overexpressing mouse Dgat2 in the intestine (Dgat2Int)
Dgat2Int mice were generated with a DNA construct containing the villin promoter/enhancer driving the expression of mouse Dgat2 (Fig. 1A). The villin promoter/enhancer drives expression in epithelial cells of the small and large intestine as well as from crypt to tip on the villus beginning as early as 12.5 dpc [24]. We generated mice with 4-fold (Dgat2Int) and 9-fold (Dgat2IntB, Supplementary data) overexpression of Dgat2 mRNA levels compared to WT mice fed a low fat, chow diet determined by QPCR. Using RT-PCR, we determined that the transgene was present along the length of the small intestine, colon, and kidney but not in muscle, liver and adipose tissue (Fig. 1B). Using QPCR we found that Dgat2 mRNA levels were only elevated in the small intestine and colon of Dgat2Int mice and not in kidney, muscle, liver or adipose tissue (Fig. 1C). Dgat1 mRNA levels were similar in the jejunum of WT and Dgat2Int mice (Fig. 1D).
A group of Dgat2Int and WT littermate controls were weaned at 3 weeks of age to a chow diet and weighed weekly until 18 weeks of age. Dgat2Int and WT littermate controls had similar body weight curves, liver and gonadal fat pad weights as well as fasting blood glucose and TG concentrations (Fig. 2A, C and D). A subgroup of Dgat2Int and WT littermate controls were switched to a HFD for 9 weeks at 10 weeks of age. Likewise, Dgat2Int and WT littermate controls fed HFD had similar body weights throughout the study (Fig. 2B). In addition, liver weights, gonadal fat pad weights, fasting plasma glucose concentrations, and dietary fat absorption were similar at the end of the study in Dgat2Int and WT littermate controls fed HFD (Fig. 2C and Table 2). Interestingly, we found increased fasting plasma TG concentration in Dgat2Int compared to WT littermate controls fed HFD (Fig. 2D).
Table 2.
Food intake g/day (n = 4–5) | Fecal weight g/day (n = 4–5) | Fecal fat % (n = 4–5) | |
---|---|---|---|
WT | 2.3 ± 0.3 | 0.21 ± 0.02 | 1.8 ± 0.4 |
Dgat1Int | 2.3 ± 0.1 | 0.25 ± 0.01 | 0.8 ± 0.1 |
Dgat2Int | 1.9 ± 0.1 | 0.24 ± 0.01 | 1.7 ± 0.2 |
3.2. Metabolic characterizations of male Dgat1Int mice
We found that male Dgat1Int mice, fed chow or HFD, have similar body weight curves, liver and gonadal fat pad weight as well as fasting plasma glucose and TG concentrations compared to WT mice (Fig. 3A–D). Likewise, food intake and dietary fat absorption were similar between Dgat1Int and WT littermate mice fed HFD (Table 2). These results were similar to previously reported data in female Dgat1Int mice [4].
3.3. Increased postprandial triglyceridemic response and intestinal TG secretion, but similar liver TG secretion, in chow-fed Dgat2Int compared to Dgat1Int and WT mice
To determine whether increased intestinal expression of Dgat1 or Dgat2 alters postprandial triglyceridemic response, we measured plasma TG concentrations hourly for up to 4 h post-acute dietary fat challenge in Dgat1Int, Dgat2Int and WT mice fed a chow diet. We found a greater postprandial triglyceridemic response as determined by increased area under the curve in Dgat2Int compared to Dgat1Int and WT mice (Fig. 4A). To determine whether the greater postprandial triglyceridemic response in Dgat2Int mice was due to an increase in intestinal TG secretion, we measured plasma TG concentration before and at 2 and 4 h post-acute dietary fat challenge in TG clearance inhibitor, Tyloxapol, treated Dgat1Int, Dgat2Int and WT mice. We found that Dgat2Int mice have increased TG secretion from enterocytes as evidenced by a faster rate of TG accumulation in the plasma during the 4-hour time course (Fig. 4B).
To confirm that the difference in TG secretion rates after an acute dietary fat challenge is due to the contribution from the small intestine and not the liver, we measured plasma TG concentrations at 0, 1, 2 and 4 h post Tyloxapol injection in Dgat1Int, Dgat2Int and WT mice. We found similar rates of TG accumulation in the plasma of Dgat1Int, Dgat2Int and WT mice (Fig. 4C).
In addition, to determine whether CM size was altered in Dgat1Int and Dgat2Int mice, we isolated CMs via ultracentrifugation 1 h post-acute dietary fat challenge and measured their size via DLS. We found that CMs isolated from the Dgat1Int and Dgat2Int mice were similar in size compared to WT mice (Table 3).
Table 3.
Z-average d.nm | Poly-dispersity index | Dominant intensity peak d.nm | |
---|---|---|---|
WT | 115 ± 6 | 0.25 ± 0.02 | 153 ± 7 |
Dgat1Int | 114 ± 6 | 0.25 ± 0.01 | 156 ± 9 |
Dgat2Int | 124 ± 3 | 0.24 ± 0.01 | 167 ± 3 |
Dgat1−/− | 58 ± 7* | 0.33 ± 0.04 | 86 ± 9* |
3.4. Decreased intestinal TG storage under chronic HF feeding and in response to an acute dietary fat challenge in Dgat1Int compared to Dgat2Int and WT mice
To determine whether increased intestinal expression of Dgat1 or Dgat2 altered TG storage in response to chronic HF feeding, we visualized TG storage via CARS microscopy in the upper jejunum of Dgat1Int, Dgat2Int and WT mice fed a HFD for 9 weeks. Similar to previously published results in female, HF-fed Dgat1Int mice [4], male, HF-fed Dgat1Int mice had less TG storage in enterocytes than WT controls (Fig. 5A). Although not statistically significant, biochemical TG analysis resulted in similar trends of lower TG concentration in the jejunum of HF-fed Dgat1Int mice compared to WT mice (Fig. 5B). We found that HF-fed Dgat2Int mice did not have differential intestinal TG storage compared to WT mice (Fig. 5A and C).
To determine whether increased intestinal expression of Dgat1 or Dgat2 altered TG storage in response to an acute dietary fat challenge, we visualized TG storage via CARS microscopy in the upper jejunum of chow-fed Dgat1Int, Dgat2Int and WT mice at 1, 2, 4 and 8 h post-acute dietary fat challenge. We found that intestine-specific overexpression of Dgat1 resulted in less TG storage in enterocytes, whereas intestine-specific overexpression of Dgat2 did not result in differential TG storage in enterocytes in response to an acute dietary fat challenge compared to WT mice (Fig. 5D). We found similar results in the lower jejunum of chow-fed Dgat1Int, Dgat2Int and WT mice at 1, 2, 4 and 8 h post-acute dietary fat challenge (data not shown).
3.5. Decreased mRNA levels for genes involved in fatty acid oxidation under HF feeding in Dgat2Int compared to Dgat1Int and WT mice
We initially predicted that if TG secretion increases then TG storage would decrease and vice versa. However, in Dgat2Int mice TG secretion increased and storage stayed the same. In Dgat1Int mice, TG storage decreased and secretion stayed the same. Another fate of fatty acids in enterocytes is oxidation [25–27]. To determine whether increased intestinal expression of Dgat1 or Dgat2 may alter fatty acid oxidation in enterocytes, mRNA levels of genes involved in fatty acid oxidation were determined in jejunum of chronic HF-fed Dgat1Int, Dgat2Int and WT mice. We measured mRNA levels of (Pparα), acyl-CoA oxidase (Acox), carnitine palmitoyltransferase 1a (Cpt1a), fatty acid binding protein 2 (Fabp2), medium chain acyl-CoA dehydrogenase (Acadm), and long chain acyl-CoA dehydrogenase (Acadl). We found remarkably lower mRNA levels of Pparα, Acox, Cpt1a, Fabp2, and Acadl in the jejunum of HF-fed Dgat2Int compared to Dgat1Int and WT mice (Fig. 6).
3.6. Increased hepatic TG storage in HF-fed Dgat2Int mice compared to WT and Dgat1Int mice
To determine whether increased intestinal expression of Dgat1 or Dgat2 resulted in a susceptibility to HFD-induced hepatic steatosis, we fed Dgat1Int and Dgat2Int mice and WT littermates a HFD for 9 weeks. Despite the liver weights being similar between Dgat2Int and WT mice, hepatic TG concentrations were significantly higher in Dgat2Int compared to WT mice fed a HFD (Fig. 7B). We did not find significant differences in liver weights or hepatic TG concentrations in Dgat1Int compared to WT mice fed a HFD (Fig. 7A). Similar hepatic TG concentrations were observed in chow-fed Dgat1Int and Dgat2Int mice and corresponding WT littermates (data not shown).
3.7. Abnormal intestinal TG accumulation in Dgat1−/− mice is reversed when crossed with Dgat1Int, but not Dgat2Int mice
To determine the specificity of DGAT1 and DGAT2 in intestinal TG metabolism, we imaged the upper jejunum of HFD-fed Dgat1−/−, Dgat1−/−Dgat1Int, and Dgat1−/−Dgat2Int mice using CARS microscopy. We found that intestinal overexpression of Dgat1, but not Dgat2 in Dgat1−/− mice corrected the abnormal intestinal TG accumulation of HFD-fed Dgat1−/− mice (Fig. 8). In addition, we characterized CM size of Dgat1−/− mice and found that the CM size in Dgat1−/− is significantly smaller compared to WT mice (Table 3).
4. Discussion
Intestinal DGAT2 is important in the cellular and physiological responses to dietary fat. We found that when the ratio of DGAT2/DGAT1 is high in enterocytes (Dgat2Int), TG secretion from enterocytes is enhanced; however, TG storage within enterocytes is similar compared to WT mice. Furthermore, we determined that a high DGAT2/DGAT1 ratio in enterocytes resulted in reduced mRNA levels of genes involved in fatty acid oxidation, suggesting that the enhanced supply of TG for secretion may in part be due to reduced fatty acid oxidation. Ultimately, this enhanced supply of TG for secretion in Dgat2Int mice may be a significant contributing factor to the elevated fasting plasma TG and increased hepatic TG stores in response to chronic HFD feeding.
We have confirmed that when present in the absence of DGAT1 (Dgat1−/−), intestinal DGAT2 contributes to the synthesis of TG for secretion, but the size of the CMs is smaller and rate of TG secretion dramatically reduced, resulting in abnormal TG storage within enterocytes. We further confirmed that when intestinal DGAT2 is present with excess DGAT1 (Dgat1Int), TG secretion from enterocytes is normal, but TG storage within enterocytes is reduced and the CLDs present appear smaller. Importantly, in all of these mouse models dietary fat absorption remained highly efficient and quantitatively similar. These results highlight that altering fatty acid and TG metabolism within enterocytes, without affecting quantitative dietary fat absorption, has the capacity to alter the systemic trafficking of dietary fat and may serve as an effective target for preventing and treating metabolic diseases such as hepatic steatosis.
Intestinal DGAT1 and DGAT2 contribute to TG synthesis for both storage and secretion. DGAT activity is primarily located in the endoplasmic reticulum (ER) of cells and has been characterized on both the cytosolic and lumenal sides of the ER membrane, referred to as overt and latent activities, respectively [28,29]. The concept of overt and latent DGAT activities proposes that TGs synthesized on the cytosolic side are destined for storage in CLDs, whereas TGs synthesized within the ER lumen are packaged for secretion on TG rich lipoproteins [30]. With the identification of two separate genes catalyzing DGAT activity, DGAT1 and DGAT2, the hypothesis that these two different proteins may be responsible for the synthesis of TG on separate sides of the ER membrane was proposed. In fact, initial topology studies of DGAT1 and DGAT2 were consistent with this idea with the active site of DGAT1 on the luminal side of the ER membrane [31,32] and the active site of DGAT2 on the cytosolic side of the ER membrane [33]. In addition to the data presented here, several pieces of evidence are inconsistent with a specific role of DGAT1 in synthesizing TG for secretion and DGAT2 in synthesizing TG for storage. First, cell types without the ability to secrete TG on lipoproteins express both DGAT1 and DGAT2 [7]. Second, overexpression of DGAT1 or DGAT2 in cells without endogenous DGAT activity results in increased TG storage in CLDs [19]. Third, more recent topology studies suggest that DGAT1 may insert into the ER membrane with at least two different topologies with the active site on either side of the ER membrane [34]. Although altering relative levels of DGAT1 and DGAT2 in enterocytes changes the balance between TG storage and secretion as shown here, fatty acid supply and other proteins likely contribute in determining the fate of newly synthesized TGs.
One factor that may play a role in determining the fate of newly synthesized TG in cells is the cellular localization of DGAT2. In addition to the ER, DGAT2 protein and activity are associated with mitochondria associated membranes, mitochondria, and cytoplasmic lipid droplets [11,35]. Although the studies presented here did not specifically identify the cellular location of overexpressed DGAT2, we found remarkably lower mRNA levels of genes related to fatty acid oxidation in intestinal mucosa of HFD-fed Dgat2Int compared to WT mice (Fig. 6). These results are consistent with our recently reported results in diet-induced obese mice where we found higher DGAT2 mRNA levels and a significant, and reduced PPARα mRNA level 2 h after a high fat challenge compared to lean mice [5]. Although levels of fatty acid oxidation in the intestine are considered low in comparison to other tissues [36,37], changes in intestinal fatty acid oxidation may alter fatty acid availability for TG synthesis and ultimately storage and secretion. In fact, dietary polyunsaturated fatty acids increase fatty acid oxidation in the intestine via a PPARα-dependent manner [25,38,39]. Furthermore, fibrate drugs, which are PPARα agonists, increase fatty acid oxidation in the small intestine and decrease the postprandial triglyceridemic response [26,40]. In Dgat2Int mice, we found reduced PPARα mRNA levels, allowing us to speculate that intestinal DGAT2 plays a role in limiting fatty acid oxidation in enterocytes by localizing to the mitochondria or mitochondria associated membranes where it may channel fatty acids away from oxidation toward TG synthesis, CM secretion and eventually increased hepatic TG storage.
DGAT1 and DGAT2 work together with complementary, but not redundant, functions in processing dietary fat by the intestine. In the absence of DGAT1, DGAT2 is able to ensure quantitative absorption of dietary fat, but in this study we found that the CMs that are made are significantly smaller than CMs made in mice with both DGAT1 and DGAT2 (Table 3). We previously demonstrated that crossing Dgat1−/− and Dgat1Int mice restores the intestine phenotype of Dgat1−/− mice including the abnormal TG storage and reduced rate of TG secretion. In addition, it restores their susceptibility to diet induced obesity and hepatic steatosis. We were curious whether adding more DGAT2 to enterocytes of Dgat1−/− mice may also complement this intestinal phenotype due to overall more DGAT activity. However, when we crossed Dgat1−/− and Dgat2Int the abnormal TG storage phenotype remained (Fig. 8).
It is important to highlight that Dgat1Int and Dgat2Int mice retain endogenous DGAT1 and DGAT2 and thus these models only tip the balance of contribution of either DGAT1 or DGAT2 toward TG synthesis. Looking beyond the intestine, we found it particularly interesting that increasing the contribution of DGAT2 in the intestine resulted in an increase in hepatic TG storage, since we and others have found that intestinal levels of DGAT2 are higher in genetic and diet-induced obesity models which have hepatic steatosis [5,20,21]. In summary, our results demonstrate that DGAT1 and DGAT2 work together to govern the number and size of CMs for TG secretion. In addition, our previous results suggest that DGAT1 and DGAT2 also govern the size of CLD for TG storage [11]. The different cellular and physiological responses to dietary fat challenges in these mouse models emphasize the distinct roles of these proteins and highlight that the relative levels of intestinal DGAT1 and DGAT2 are likely important in determining the response to dietary fat including regulation of postprandial blood TG levels as well as the development of HFD-induced hepatic steatosis.
Supplementary Material
Acknowledgments
This work was supported by AHA NCRP Scientist Development Grant 0835203 N to KKB, NIH R01EB7243 to JXC and AHA Predoctoral Fellowship 11PRE5140017 to AU.
Abbreviations
- CM
chylomicrons
- CARS
coherent anti-Stokes Raman scattering
- CLD
cytoplasmic lipid droplets
- DLS
dynamic light scattering
- DGAT
diacylglycerol acyltransferase
- HFD
high-fat diet
- TG
triacylglycerol
- WT
wild-type
Footnotes
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.bbalip.2013.04.013.
References
- 1.Carey MC, Small DM, Bliss CM. Lipid digestion and absorption. Annu Rev Physiol. 1983;45:651–677. doi: 10.1146/annurev.ph.45.030183.003251. [DOI] [PubMed] [Google Scholar]
- 2.Zhu JB, Lee BG, Buhman KK, Cheng JX. A dynamic, cytoplasmic triacylglycerol pool in enterocytes revealed by ex vivo and in vivo coherent anti-Stokes Raman scattering imaging. J Lipid Res. 2009;50:1080–1089. doi: 10.1194/jlr.M800555-JLR200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Robertson MD, Parkes M, Warren BF, Ferguson DJP, Jackson KG, Jewell DP, Frayn KN. Mobilisation of enterocyte fat stores by oral glucose in humans. Gut. 2003;52:834–839. doi: 10.1136/gut.52.6.834. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Lee B, Fast AM, Zhu J, Chen JX, Buhman KK. Intestine specific expression of acyl CoA:diacylgylcerol acyltransferase 1 (DGAT1) reverses resistance to diet-induced hepatic steatosis and obesity in Dgat1−/− mice. J Lipid Res. 2010;51:1770–1780. doi: 10.1194/jlr.M002311. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Uchida A, Whitsitt MC, Eustaquio T, Slipchenko MN, Leary JF, Cheng JX, Buhman KK. Reduced triglyceride secretion in response to an acute dietary fat challenge in obese compared to lean mice. Front Physiol. 2012;3:26. doi: 10.3389/fphys.2012.00026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Yen CLE, Cheong ML, Grueter C, Zhou P, Moriwaki J, Wong JS, Hubbard B, Marmor S, Farese RV. Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding. Nat Med. 2009;15:442–446. doi: 10.1038/nm.1937. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, Novak S, Collins C, Welch CB, Lusis AJ, Erickson SK, Farese RV., Jr Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci U S A. 1998;95:13018–13023. doi: 10.1073/pnas.95.22.13018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Buhman KK, Smith SJ, Stone SJ, Repa JJ, Wong JS, Knapp FF, Burri BJ, Hamilton RL, Abumrad NA, Farese RV. DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem. 2002;277:25474–25479. doi: 10.1074/jbc.M202013200. [DOI] [PubMed] [Google Scholar]
- 9.Cases S, Stone SJ, Zhou P, Yen E, Tow B, Lardizabal KD, Voelker T, Farese RV. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem. 2001;276:38870–38876. doi: 10.1074/jbc.M106219200. [DOI] [PubMed] [Google Scholar]
- 10.Haas JT, Winter HS, Lim E, Kirby A, Blumenstiel B, DeFelice M, Gabriel S, Jalas C, Branski D, Grueter CA, Toporovski MS, Walther TC, Daly MJ, Farese RV., Jr DGAT1 mutation is linked to a congenital diarrheal disorder. J Clin Invest. 2012;122:4680–4684. doi: 10.1172/JCI64873. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Wilfling F, Wang H, Haas JT, Krahmer N, Gould TJ, Uchida A, Cheng JX, Graham M, Christiano R, Frohlich F, Liu X, Buhman KK, Coleman RA, Bewersdorf J, Farese RV, Jr, Walther TC. Triacylglycerol synthesis enzymes mediate lipid droplet growth by relocalizing from the ER to lipid droplets. Dev Cell. 2013;24:384–399. doi: 10.1016/j.devcel.2013.01.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Stone SJ, Levin MC, Zhou P, Han JY, Walther TC, Farese RV. The endoplasmic reticulum enzyme DGAT2 is found in mitochondria-associated membranes and has a mitochondrial targeting signal that promotes its association with mitochondria. J Biol Chem. 2009;284:5352–5361. doi: 10.1074/jbc.M805768200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV., Jr Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res. 2008;49:2283–2301. doi: 10.1194/jlr.R800018-JLR200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Liu Q, Siloto RM, Lehner R, Stone SJ, Weselake RJ. Acyl-CoA:diacylglycerol acyltransferase: molecular biology, biochemistry and biotechnology. Prog Lipid Res. 2012;51:350–377. doi: 10.1016/j.plipres.2012.06.001. [DOI] [PubMed] [Google Scholar]
- 15.Dow RL, Li JC, Pence MP, Gibbs EM, LaPerle JL, Litchfield J, Piotrowski DW, Munchhof MJ, Manion TB, Zavadoski WJ, Walker GS, McPherson RK, Tapley S, Sugarman E, Guzman-Perez A, DaSilva-Jardine P. Discovery of PF-04620110, a potent, selective, and orally bioavailable inhibitor of DGAT-1. ACS Med Chem Lett. 2011;2:407–412. doi: 10.1021/ml200051p. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Cheng D, Iqbal J, Devenny J, Chu CH, Chen LP, Dong J, Seethala R, Keim WJ, Azzara AV, Lawrence RM, Pelleymounter MA, Hussain MM. Acylation of acylglycerols by acyl coenzyme A:diacylglycerol acyltransferase 1 (DGAT1) functional importance of DGAT1 in intestinal fat absorption. J Biol Chem. 2008;283:29802–29811. doi: 10.1074/jbc.M800494200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Jadhav RD, Kadam KS, Kandre S, Guha T, Reddy MM, Brahma MK, Deshmukh NJ, Dixit A, Doshi L, Potdar N, Enose AA, Vishwakarma RA, Sivaramakrishnan H, Srinivasan S, Nemmani KV, Gupte A, Gangopadhyay AK, Sharma R. Synthesis and biological evaluation of isoxazole, oxazole, and oxadiazole containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors. Eur J Med Chem. 2012;54:324–342. doi: 10.1016/j.ejmech.2012.05.016. [DOI] [PubMed] [Google Scholar]
- 18.Yeh VS, Beno DW, Brodjian S, Brune ME, Cullen SC, Dayton BD, Dhaon MK, Falls HD, Gao J, Grihalde N, Hajduk P, Hansen TM, Judd AS, King AJ, Klix RC, Larson KJ, Lau YY, Marsh KC, Mittelstadt SW, Plata D, Rozema MJ, Segreti JA, Stoner EJ, Voorbach MJ, Wang X, Xin X, Zhao G, Collins CA, Cox BF, Reilly RM, Kym PR, Souers AJ. Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1. J Med Chem. 2012;55:1751–1757. doi: 10.1021/jm201524g. [DOI] [PubMed] [Google Scholar]
- 19.Stone SJ, Myers HM, Watkins SM, Brown BE, Feingold KR, Elias PM, Farese RV. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem. 2004;279:11767–11776. doi: 10.1074/jbc.M311000200. [DOI] [PubMed] [Google Scholar]
- 20.Douglass JD, Malik N, Chon SH, Wells K, Zhou YX, Choi AS, Joseph LB, Storch J. Intestinal mucosal triacylglycerol accumulation secondary to decreased lipid secretion in obese and high fat fed mice. Front Physiol. 2012;3:25. doi: 10.3389/fphys.2012.00025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Wakimoto K, Chiba H, Michibata H, Seishima M, Kawasaki S, Okubo K, Mitsui H, Torii H, Imai Y. A novel diacylglycerol acyltransferase (DGAT2) is decreased in human psoriatic skin and increased in diabetic mice, Biochem. Biophys Res Commun. 2003;310:296–302. doi: 10.1016/j.bbrc.2003.09.015. [DOI] [PubMed] [Google Scholar]
- 22.Werner A, Havinga R, Perton F, Kuipers F, Verkade HJ. Lymphatic chylomicron size is inversely related to biliary phospholipid secretion in mice. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1177–G1185. doi: 10.1152/ajpgi.00127.2005. [DOI] [PubMed] [Google Scholar]
- 23.Sakurai T, Trirongjitmoah S, Nishibata Y, Namita T, Tsuji M, Hui SP, Jin S, Shimizu K, Chiba H. Measurement of lipoprotein particle sizes using dynamic light scattering. Ann Clin Biochem. 2010;47:476–481. doi: 10.1258/acb.2010.010100. [DOI] [PubMed] [Google Scholar]
- 24.Madison BB, Dunbar L, Qiao XT, Braunstein K, Braunstein E, Gumucio DL. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem. 2002;277:33275–33283. doi: 10.1074/jbc.M204935200. [DOI] [PubMed] [Google Scholar]
- 25.van Schothorst EM, Flachs P, Hal NL Franssen-van, Kuda O, Bunschoten A, Molthoff J, Vink C, Hooiveld GJ, Kopecky J, Keijer J. Induction of lipid oxidation by polyunsaturated fatty acids of marine origin in small intestine of mice fed a high-fat diet. BMC Genomics. 2009;10:110. doi: 10.1186/1471-2164-10-110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Uchida A, Slipchenko MN, Cheng JX, Buhman KK. Fenofibrate, a peroxisome proliferator-activated receptor a agonist, alters triglyceride metabolism in enterocytes of mice. Biochim Biophys Acta, Mol Cell Biol Lipids. 2011;1811:170–176. doi: 10.1016/j.bbalip.2010.12.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Storch J, Zhou YX, Lagakos WS. Metabolism of apical versus basolateral sn-2-monoacylglycerol and fatty acids in rodent small intestine. J Lipid Res. 2008;49:1762–1769. doi: 10.1194/jlr.M800116-JLR200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Owen M, Zammit VA. Evidence for overt and latent forms of DGAT in rat liver microsomes. Implications for the pathways of triacylglycerol incorporation into VLDL. Biochem Soc Trans. 1997;25:21S. doi: 10.1042/bst025021s. [DOI] [PubMed] [Google Scholar]
- 29.Owen MR, Corstorphine CC, Zammit VA. Overt and latent activities of diacylglycerol acytransferase in rat liver microsomes: possible roles in very-low-density lipoprotein triacylglycerol secretion. Biochem J. 1997;323:17–21. doi: 10.1042/bj3230017. Pt 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Sturley SL, Hussain MM. Lipid droplet formation on opposing sides of the endoplasmic reticulum. J Lipid Res. 2012;53:1800–1810. doi: 10.1194/jlr.R028290. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Cheng D, Meegalla RL, He B, Cromley DA, Billheimer JT, Young PR. Human acyl-CoA:diacylglycerol acyltransferase is a tetrameric protein. Biochem J. 2001;359:707–714. doi: 10.1042/0264-6021:3590707. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Yu C, Chen J, Lin S, Liu J, Chang CC, Chang TY. Human acyl-CoA:cholesterol acyltransferase-1 is a homotetrameric enzyme in intact cells and in vitro. J Biol Chem. 1999;274:36139–36145. doi: 10.1074/jbc.274.51.36139. [DOI] [PubMed] [Google Scholar]
- 33.Stone SJ, Levin MC, Farese RV., Jr Membrane topology and identification of key functional amino acid residues of murine acyl-CoA:diacylglycerol acyltransferase-2. J Biol Chem. 2006;281:40273–40282. doi: 10.1074/jbc.M607986200. [DOI] [PubMed] [Google Scholar]
- 34.Wurie HR, Buckett L, Zammit VA. Evidence that diacylglycerol acyltransferase 1 (DGAT1) has dual membrane topology in the endoplasmic reticulum of HepG2 cells. J Biol Chem. 2011;286:36238–36247. doi: 10.1074/jbc.M111.251900. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Kuerschner L, Moessinger C, Thiele C. Imaging of lipid biosynthesis: how a neutral lipid enters lipid droplets. Traffic. 2008;9:338–352. doi: 10.1111/j.1600-0854.2007.00689.x. [DOI] [PubMed] [Google Scholar]
- 36.Windmueller HG, Spaeth AE. Identification of ketone bodies and glutamine as the major respiratory fuels in vivo for postabsorptive rat small intestine. J Biol Chem. 1978;253:69–76. [PubMed] [Google Scholar]
- 37.Lagakos WS, Gajda AM, Agellon L, Binas B, Choi V, Mandap B, Russnak T, Zhou YX, Storch J. Different functions of intestinal and liver-type fatty acid-binding proteins in intestine and in whole body energy homeostasis. Am J Physiol Gastrointest Liver Physiol. 2011;300:G803–G814. doi: 10.1152/ajpgi.00229.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.de Vogel-van HM, den Bosch M, de Bunger PJ, Groot H, Bosch-Vermeulen G, Muller Hooiveld M. PPARalpha-mediated effects of dietary lipids on intestinal barrier gene expression. BMC Genomics. 2008;9:231. doi: 10.1186/1471-2164-9-231. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Mori T, Kondo H, Hase T, Tokimitsu I, Murase T. Dietary fish oil upregulates intestinal lipid metabolism and reduces body weight gain in C57BL/6J mice. J Nutr. 2007;137:2629–2634. doi: 10.1093/jn/137.12.2629. [DOI] [PubMed] [Google Scholar]
- 40.Kimura R, Takahashi N, Murota K, Yamada Y, Niiya S, Kanzaki N, Murakami Y, Moriyama T, Goto T, Kawada T. Activation of peroxisome proliferator-activated receptor-alpha (PPAR alpha) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes. Biochem Biophys Res Commun. 2011;410:1–6. doi: 10.1016/j.bbrc.2011.05.057. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.